Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer 2015, 136(5):E359-E386
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 201810.3322/caac.21492.
Odedina FT, Ogunbiyi JO, Ukoli FAM: Roots of prostate cancer in African-American men. J Natl Med Assoc 2006, 98(4):539–543
Cassell A, Yunusa B, Jalloh M, Ndoye M, Mbodji MM, Diallo A, Kouka SC, Labou I, Niang L, Gueye SM. Management of Advanced and Metastatic Prostate Cancer: A Need for a Sub-Saharan Guideline. J Oncol. 2019;2019:1785428–1785428. https://doi.org/10.1155/2019/1785428.
Global Cancer Observatory: Cancer today https://gco.iarc.fr/
Chamberlain J, Melia J, Moss S, Brown J: The diagnosis, management, treatment and costs of prostate cancer in England and Wales. Health Technology Assessment (Winchester, England) 1997, 1(3):i
Eniu A, Carlson RW, Aziz Z, Bines J, Hortobágyi GN, Bese NS, Love RR, Vikram B, Kurkure A, Anderson BO: Breast cancer in limited-resource countries: treatment and allocation of resources. The breast journal 2006, 12 Suppl 1:S38-5310.1111/j.1075-122X.2006.00202.x.
Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65(6):1046–55. https://doi.org/10.1016/j.eururo.2013.12.062.
Hao S, Östensson E, Eklund M, Grönberg H, Nordström T, Heintz E, Clements M. The economic burden of prostate cancer – a Swedish prevalence-based register study. BMC Health Services Research. 2020;20(1):448. https://doi.org/10.1186/s12913-020-05265-8.
Mittmann N, Liu N, Cheng SY, Seung SJ, Saxena FE, Hong NJL, Earle CC, Cheung MC, Leighl NB, Coburn NG: Health system costs for cancer medications and radiation treatment in Ontario for the 4 most common cancers: a retrospective cohort study. CMAJ open 2020, 8(1):E191
Mojahedian MM, Toroski M, Keshavarz K, Aghili M, Zeyghami S, Nikfar S: Estimating the Cost of Illness of Prostate Cancer in Iran. Clinical therapeutics 2019, 41(1):50–58
Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. The Lancet Oncology. 2013;14(12):1165–74. https://doi.org/10.1016/S1470-2045(13)70442-X.
Lee K-S, Chang H-S, Lee S-M, Park E-C: Economic burden of cancer in Korea during 2000-2010. Cancer research and treatment: official journal of Korean Cancer Association 2015, 47(3):387
Kingdom of Eswatini:The 2017 Population and Housing Census Preliminary Results 2017,http://www.gov.sz/images/planningministry/Volume-3-1.pdf.
WorldBank:The Kingdom of Eswatini Toward Equal Opportunity: Accelerating Inclusion and Poverty Reduction. Systematic Country Diagnostic. 2020.,https://www.hdl.handle.net/10986/34970
WorldBank: World Bank WDI and M acro Poverty Outlook. In.: World Bank; 2015.
UNICEF Eswatini: Health Budget Brief Report. 2018/19
Ngcamphalala C, Ataguba JE. An assessment of financial catastrophe and impoverishment from out-of-pocket health care payments in Swaziland. Global Health Action. 2018;11(1):1428473. https://doi.org/10.1080/16549716.2018.1428473.
Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW: Methods for the economic evaluation of health care programmes: Oxford university press; 2015
Hodgson TA, Meiners MR: Cost-of-Illness Methodology: A Guide to Current Practices and Procedures. The Milbank Memorial Fund Quarterly Health and Society 1982, 60(3):429-46210.2307/3349801.
Mogyorosy Z, Smith P:The main methodological issues in costing health care services: a literature review.2005
Cebisile NE, Ostensson; Themba, G, Ginindza.: The Societal costs of Breast Cancer In Eswatini. In.: University of KwaZulu Natal; 2020.
Ministry of Health:Eswatini Standardized Cancer Care and Guidelines.2020
Sobin LH, Gospodarowicz MK, Wittekind C: TNM classification of malignant tumours: John Wiley & Sons; 2011
Ministry of health:Phalala Fund Annual Report.2018
Ministry of Health: Swaziland National Cancer Registry Report on Cases of cancers in Swaziland In.; 2016.
Östensson E, Hellström A-C, Hellman K, Gustavsson I, Gyllensten U, Wilander E, Zethraeus N, Andersson S: Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program. Acta Obstetricia et Gynecologica Scandinavica 2013, 92(7):830-84010.1111/aogs.12143.
Hanly P, Soerjomataram I, Sharp L. Measuring the societal burden of cancer: the cost of lost productivity due to premature cancer-related mortality in Europe. Int J Cancer. 2015;136(4):E134-145. https://doi.org/10.1002/ijc.29105.
Gold M: Panel on cost-effectiveness in health and medicine. Medical care 1996, 34(12):DS197-DS199
Krahn MD, Zagorski B, Laporte A, Alibhai SM, Bremner KE, Tomlinson G, Warde P, Naglie G: Healthcare costs associated with prostate cancer: estimates from a population-based study. BJU international 2010, 105(3):338–346
Penson DF, Schonfeld WH, Flanders SC, Henke CJ, Warolin KL, Carroll PR, Litwin MS: Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: results from the CAPSURE database. Urology 2001, 57(3):499–503
Sangar VK, Ragavan N, Matanhelia SS, Watson MW, Blades RA: The economic consequences of prostate and bladder cancer in the UK. BJU international 2005, 95(1):59–63
Cronin P, Kirkbride B, Bang A, Parkinson B, Smith D, Haywood P: Long-term health care costs for patients with prostate cancer: a population‐wide longitudinal study in New South Wales, Australia. Asia‐Pacific Journal of Clinical Oncology 2017, 13(3):160–171
Roehrborn CG, Albertsen P, Stokes ME, Black L, Benedict A. First-year costs of treating prostate cancer: estimates from SEER-Medicare data. Prostate Cancer and Prostatic Diseases. 2009;12(4):355–60. https://doi.org/10.1038/pcan.2009.21.
Moyer VA: Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Annals of internal medicine 2012, 157(2):120–134
Moss SM, Melia J: Screening for prostate cancer: the current position. British Medical Bulletin 1998, 54(4):791–805 10.1093/oxfordjournals.bmb.a011730
Olapade-Olaopa EO, Obamuyide HA, Yisa GT: Management of advanced prostate cancer in Africa. The Canadian journal of urology 2008, 15(1):3890–3898
Abbas F, Scardino PT: The natural history of clinical prostate carcinoma. Cancer 1997, 80(5):827-833 10.1002/(sici)1097-0142(19970901)
Molinier L, Bauvin E, Combescure C, Castelli C, Rebillard X, Soulié M, Daurès J-P, Grosclaude P: Methodological Considerations in Cost of Prostate Cancer Studies: A Systematic Review. Value in Health 2008, 11(5):878–885https://doi.org/10.1111/j.1524-4733.2008.00327.x.
Rencz F, Brodszky V, Varga P, Gajdácsi J, Nyirády P, Gulácsi L: The economic burden of prostate cancer. A systematic literature overview of registry-based studies. Orvosi Hetilap 2014, 155(13):509–520
Cebisile NE, Östensson; Themba, G, Ginindza.: The Economic Burden of Cervical Cancer in Eswatini. In.: University of KwaZulu Natal; 2020.
Kirby RS, Fitzpatrick JM, Irani J: Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3). BJU International 2009, 103(4):441-44510.1111/j.1464-410X.2008.08280.x.